{"entity":{"id":"mitazalimab","kind":"drug","name":"Mitazalimab","aka":["ADC-1013","JNJ-64457107"],"tldr":"Mitazalimab is a CD40 agonist antibody from Alligator Bioscience AB, in registered phase 2 trials for pancreatic ductal adenocarcinoma.","summary":"Mitazalimab is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Alligator Bioscience AB, in pancreatic ductal adenocarcinoma. It is a human CD40 agonistic IgG1 antibody, given with modified FOLFIRINOX in the OPTIMIZE-1 study (NCT04888312, Lancet Oncology 2024). OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Mitazalimab","url":"https://clinicaltrials.gov/search?intr=Mitazalimab"},{"label":"OPTIMIZE-1: CD40 agonist mitazalimab with mFOLFIRINOX in metastatic pancreatic cancer (Lancet Oncology 2024)","url":"https://doi.org/10.1016/s1470-2045(24)00263-8"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":["cd40"],"drugs":[],"companies":["alligator-bioscience"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04888312"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"modality":"Monoclonal antibody (CD40 agonist)","mechanism":"A human IgG1 antibody that switches on CD40, the receptor on dendritic cells and macrophages that licenses them to prime T cells (OPTIMIZE-1, Lancet Oncology 2024). Despite the code ADC-1013 it is not an antibody-drug conjugate and carries no payload.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/mitazalimab/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"cd40","kind":"target","name":"CD40","route":"/targets/cd40/"}],"company":[{"id":"alligator-bioscience","kind":"company","name":"Alligator Bioscience","route":"/companies/alligator-bioscience/"}],"trial":[{"id":"nct07199764","kind":"trial","name":"Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer","route":"/trials/nct07199764/"},{"id":"nct04888312","kind":"trial","name":"Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients","route":"/trials/nct04888312/"}],"term":[{"id":"tumor-associated-macrophages","kind":"term","name":"Tumour-associated macrophages (TAMs)","route":"/terms/tumor-associated-macrophages/"}]}}